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Purpose




An 18 year old male presented with a rash of three weeks
duration. Soon after the rash appeared, he developed
pain and swelling of the right hand, as well as numbness
and tingling of the right forearm. A recreational weight
lifter, he noticed progressively decreasing stamina and
amount of weight that he could lift. Swelling of the eye-
lids and bridge of nose prompted treatment for an aller-
gic reaction, but these signs did not improve with
antihistamines and oral corticosteroids. Family history
was significant for the patient’s father and paternal
grandfather both having a history of Idiopathic Throm-
bocytopenic Purpura. Physical exam revealed 2-3 mm
skin-colored papules scattered on arms and thorax, with
prominent areas at the base of neck and shoulders.
Periorbital and glabellar swelling were visible, and
bogginess of the left 3rd metacarpalphalengeal joint was
present. Strength was decreased in arms and legs, 3/5
and 4/5 respectively. Sensation for pin-prick and vibra-
tion was decreased in a stocking/glove distribution of
the distal extremities. He had a fine tremor of the ton-
gue and right arm. A shaved skin biopsy showed a
papule with prominent mucin deposition (alcian blue
staining) and increased fibroblast cellularity.
Bone marrow aspirate showed mild hypocellularity
with 2-3% plasma cells (polyclonal). Serum IgE level was
884 IU/mL, however serum protein electrophoresis and
immunoelectrophoresis were normal. Electromyography
(EMG) was consistent with a sensory/motor peripheral
polyneuropathy with demyelinating and axonal features
involving the arms. Additional laboratory workup for
underlying autoimmune, thyroid, neurologic, infectious
and neoplastic disease was negative. Based on histo-
pathology and clinical features, he was diagnosed with
Scleromyxedema, and therapy with intravenous immu-
noglobulin (IVIg) was initiated with moderate sympto-
matic improvement after the first infusion. After three
infusions, there was complete resolution of symptoms,
and he had a normal physical exam without rash or
neurologic abnormalities. He was treated with IVIg for a
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total of 6 months, and has not experienced symptoms
suggesting relapse during the 6 months after disconti-
nuation of IVIg. Repeat EMG testing, 3 and 9 months
post-presentation showed significant improvement, but
persistence of very mild peripheral neuropathy.
Conclusion
To our knowledge, this patient is the youngest male
reported in the literature to have Scleromyxedema with-
out an associated autoimmune disease, and this case
supports the benefit of IVIg for the treatment of
Scleromyxedema.
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